AbbVie, Galapagos’ Kalydeco challenger clears phase 2
Galapagos has posted phase 2 data on the cystic fibrosis drug it is developing with AbbVie. The data suggest the potentiator can play a...
Kaftrio Boosts Exercise Capacity in Teens With CF, Case Analysis Shows
A six-week treatment with Kaftrio led to marked improvement in exercise capacity in adolescents with cystic fibrosis (CF), according to...
Prioritizing treatment burden important for patients with cystic fibrosis
Findings published in Chest highlighted the importance of routinely capturing treatment burden among individuals with cystic fibrosis in...
Change of antibiotic is not associated with improved expiratory volume response in patients with fib
Although advances in treatment lead to improvements in care, change does not reflect changes in the patient. Pulmonary exacerbation is...
Most Adults in CF Study Have Low Bone Mineral Density
More than half of adults with cystic fibrosis (CF) who underwent assessments of bone mineral density at a U.S. center had...
Cells That Represent The Airways Of Cystic Fibrosis Patients Created
“This model system can be used to identify new treatments for those CF patients who continue to struggle without therapies. More broadly,...
Translate Bio's mRNA fails to improve lung function in cystic fibrosis patients
A small clinical trial has found no pattern of improvements in lung function in cystic fibrosis patients who received Translate Bio’s...
Study finds delays in initial cystic fibrosis evaluation in infants of color
Delays in diagnosis and treatment may exacerbate long-standing health disparities Source: Ann & Robert H. Lurie Children's Hospital of...
Allergies to Beta-lactam Antibiotics Most Common Type in CF Children
by Lindsey Shapiro, PhD | July 29, 2022 Allergies to beta-lactam antibiotics were the most commonly confirmed antibiotic allergy in...
Study: Cancer Cells Move Faster in Mucus
Key Points: Scientists have discovered that cancer cells and fibroblasts travel more quickly through viscous fluids than they do through...
